PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment

Background Practice guidelines recommend using panitumumab in combination with chemotherapy to treat KRAS wild-type (WT) metastatic colorectal cancer (mCRC) patients where it was shown to significantly extend progression-free survival (PFS) and overall survival (OS). Still, a proportion of patients will not achieve this goal. We propose a simplified predictive score to identify patients who are…

Topazium selected as a contributor in the Biogen Accelerator

This exclusive initiative, spearheaded by Biogen (https://www.biogen.com/) and HLTH Inc. (https://hlth.com/), aims to accelerate innovation in the field of rare neuromuscular diseases, with a strong focus on early diagnosis and patient engagement. Topazium, selected from hundreds of applicants after a rigorous three-month evaluation process, is one of five companies chosen to bring AI-driven solutions to…

Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency

Background: Diagnosis of hereditary angioedema (HAE) poses challenges because of its rarity and its overlapping symptoms with allergic and gastrointestinal conditions, resulting in misdiagnosis. Objective: We developed a predictive score using clinical variables for suspected HAE patients with C1 inhibitor deficiency (HAE-C1INH) to increase suspicion of HAE and thus improve diagnosis. Methods: The HADES (HAE…